Compare Moderna, Inc. (MRNA) vs SkyWest Inc (SKYW) Price & Performance

Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.

Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.

SkyWest (SKYW) trades at $96.52, down 0.12% with a bearish technical signal despite strong analyst support. The stock shows mixed earnings performance with Q1 2026 beating expectations but Q4 2025 and Q2 2026 missing estimates. Fundamentally, the company maintains solid profitability with 9.78% net margin and attractive valuation metrics including a P/E of 9.6. Recent news highlights fleet modernization efforts and expanding flying agreements while executives have been selling shares.

The outlook remains cautiously optimistic with a $112 consensus price target representing 16% upside potential. Key opportunities include fleet expansion and strong cash flow generation, while risks involve cost pressures and recent insider selling activity. The stock presents a value opportunity given its below-market valuation multiples and positive analyst coverage.